TipRanks
Advertisement
Advertisement

CH:IDIA Stock Latest News

Idorsia price target raised to CHF 6 from CHF 5 at H.C. Wainwright
The FlyIdorsia price target raised to CHF 6 from CHF 5 at H.C. Wainwright
25d ago
Idorsia price target raised to CHF 5.50 from CHF 4.50 at Deutsche Bank
PremiumThe Fly
Idorsia price target raised to CHF 5.50 from CHF 4.50 at Deutsche Bank
2M ago
Idorsia price target raised to CHF 4.50 from CHF 4 at Deutsche Bank
PremiumThe Fly
Idorsia price target raised to CHF 4.50 from CHF 4 at Deutsche Bank
4M ago
PremiumRatings
Idorsia Maintained at Buy as New Phase 3 Data Strengthen Aprocitentan Profile; 12‑Month Price Target Reaffirmed at CHF5
4M ago
PremiumRatings
Buy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
5M ago
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
PremiumRatingsIdorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
6M ago
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
Premium
Ratings
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
7M ago
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
Premium
Ratings
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
7M ago
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
PremiumThe Fly
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
7M ago
Idorsia Earnings Call Signals Turnaround, Risks Linger
PremiumCompany Announcements
Idorsia Earnings Call Signals Turnaround, Risks Linger
7M ago
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
PremiumRatings
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
8M ago
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
PremiumRatings
Idorsia: Latin America QUVIVIQ Deal and Pipeline Optionality De‑Risk Path to Profitability, Supporting Reiterated Buy Rating
8M ago
Idorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
PremiumRatingsIdorsia: Differentiated Insomnia and Hypertension Assets, Understated Guidance, and Pipeline Upside Support Reiterated Buy Rating
9M ago
Premium
Ratings
Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside
9M ago
Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential
Premium
Ratings
Buy Rating for Idorsia Driven by Promising Aprocitentan Trial Results and Market Potential
10M ago
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
PremiumThe Fly
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
10M ago
Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating
PremiumRatings
Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating
12M ago
Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts
PremiumRatings
Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts
1y ago
Idorsia upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
Idorsia upgraded to Buy from Neutral at H.C. Wainwright
1y ago
Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank
PremiumThe FlyIdorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank
1y ago
Idorsia Ltd Earnings Call: Strong Growth Amid Challenges
Premium
Company Announcements
Idorsia Ltd Earnings Call: Strong Growth Amid Challenges
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >